L-Vax: A feasibility study using a DNP-modified autologous tumor cell vaccine as therapy in patients with resectable non-small cell lung cancer.

Trial Profile

L-Vax: A feasibility study using a DNP-modified autologous tumor cell vaccine as therapy in patients with resectable non-small cell lung cancer.

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 11 Dec 2015

At a glance

  • Drugs Lung cancer vaccine (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors AVAX Technologies
  • Most Recent Events

    • 02 Dec 2015 Status changed from suspended to discontinued as reported by ClinicalTrials.gov record.
    • 09 Feb 2010 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
    • 09 Feb 2010 Planned end date changed from 1 Dec 2009 to 1 Jan 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top